Hemera Biosciences

Also Clin1 wet AMD

Hemera Biosciences is developing gene therapies to treat age-related macular degeneration (AMD). As the biology driving AMD is better understood, more effective therapies can be developed. Using the understanding of inflammation and the complement system in driving AMD, Hemera has developed HMR59, a one-time gene therapy. The therapy causes retinal cells to continuously make a soluble protein called CD59 that can block the final step of the complement cascade. HMR59 can be injected via a routine office visit and is currently being evaluated in FDA-approved trials for both dry and wet age-related macular degeneration.

Jobs: